{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:01:19Z","timestamp":1760385679862,"version":"3.37.3"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n Cientifica Rodrigo Vesga Meneses"},{"DOI":"10.13039\/501100005278","name":"Universidad de Antioquia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211096","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T18:35:42Z","timestamp":1549478142000},"page":"e0211096","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-786X","authenticated-orcid":true,"given":"Maria","family":"Agudelo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres F.","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Vesga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e10744","DOI":"10.1371\/journal.pone.0010744","article-title":"Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model","volume":"5","author":"AF Zuluaga","year":"2010","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2334-10-153","article-title":"In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin","volume":"10","author":"CA Rodriguez","year":"2010","journal-title":"BMC Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.01044-09","article-title":"Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator","volume":"54","author":"O Vesga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/AAC.00350-13","article-title":"Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem","volume":"58","author":"M Agudelo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s13104-015-1507-z","article-title":"Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model","volume":"8","author":"AF Zuluaga","year":"2015","journal-title":"BMC Res Notes"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2016.10.011","article-title":"In vivo pharmacodynamics of piperacillin\/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products","volume":"49","author":"CA Rodriguez","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/AAC.06012-11","article-title":"Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole","volume":"56","author":"M Agudelo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.03633-14","article-title":"Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin","volume":"59","author":"CA Rodriguez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"e0141872","DOI":"10.1371\/journal.pone.0141872","article-title":"Demonstration of therapeutic equivalence of fluconazole generic products in the neutropenic mouse model of disseminated candidiasis","volume":"10","author":"JM Gonzalez","year":"2015","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijantimicag.2014.10.014","article-title":"Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin\/tazobactam","volume":"45","author":"M Agudelo","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10156-012-0437-0","article-title":"Generic antibiotics in Japan","volume":"18","author":"S Fujimura","year":"2012","journal-title":"J Infect Chemother"},{"key":"ref12","unstructured":"Generic Pharmaceutical Association. Generic drug savings in the U.S. Sixth Annual Edition: 2014. Accessed April 19, 2016, <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.gphaonline.org\/media\/cms\/GPhA_Savings_Report.9.10.14_FINAL.pdf\" xlink:type=\"simple\">http:\/\/www.gphaonline.org\/media\/cms\/GPhA_Savings_Report.9.10.14_FINAL.pdf<\/ext-link>"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jinf.2007.09.011","article-title":"Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime","volume":"56","author":"E Mastoraki","year":"2008","journal-title":"J Infect"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jinf.2009.08.005","article-title":"Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia","volume":"59","author":"CA Rodriguez","year":"2009","journal-title":"J Infect"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/AAC.05129-11","article-title":"Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model","volume":"56","author":"CA Rodriguez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e0155806","DOI":"10.1371\/journal.pone.0155806","article-title":"Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam","volume":"11","author":"CA Rodriguez","year":"2016","journal-title":"PLoS One"},{"key":"ref17","unstructured":"Alliance for Human Research Protection. Former FDA Commissioner says FDA lost public trust: 17 Oct 2005. Accessed April 19, 2016, <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ahrp.org\/former-fda-commissioner-says-fda-lost-public-trust\/\" xlink:type=\"simple\">http:\/\/ahrp.org\/former-fda-commissioner-says-fda-lost-public-trust\/<\/ext-link>]."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"KM Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing, approved standard M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-9-1","article-title":"Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics","volume":"9","author":"AF Zuluaga","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AEM.14.2.170-177.1966","article-title":"Simplified, accurate method for antibiotic assay of clinical specimens","volume":"14","author":"JV Bennett","year":"1966","journal-title":"Appl Microbiol"},{"key":"ref22","first-page":"230","article-title":"Primer of biostatistics","author":"SA Glantz","year":"2002"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/AAC.26.1.78","article-title":"Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography","volume":"26","author":"CM Myers","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/AAC.01721-09","article-title":"Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance","volume":"54","author":"A Louie","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric pharmacometric modeling and simulation package for R","volume":"34","author":"M Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2334-6-55","article-title":"Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases","volume":"6","author":"AF Zuluaga","year":"2006","journal-title":"BMC Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195171792.001.0001","article-title":"Fitting models to biological data using linear and nonlinear regression","author":"H Motulsky","year":"2004"},{"key":"ref28","first-page":"1260","article-title":"Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists","volume":"298","author":"A Christopoulos","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"ref29","unstructured":"Unites States Pharmacopoeia (USP)\u2014National Formulary [USP 29\u2014NF 24]. Volume 27(1). Rockville, MD: United States Pharmacopeial Convention, Inc; 2005. [MDANT05] Monograph Development\u2014Antibiotics; p. 1110."},{"key":"ref30","unstructured":"National Center for Biotechnology Information. PubChem Compound Database; CID = 104838, <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/104838\" xlink:type=\"simple\">https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/104838<\/ext-link> (accessed May 5, 2017)."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.21.3.390","article-title":"Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis","volume":"21","author":"P Patamasucon","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/AAC.29.4.670","article-title":"Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections","volume":"29","author":"RF Jacobs","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","unstructured":"Merck. Primaxin, product monograph (imipenem and cilatatin sodium for injection, USP), I.V. infusion, antibiotic. Kirkland (Quebec). Merck Canada Inc. August 25, 2015, <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.merck.ca\/assets\/en\/pdf\/products\/PRIMAXIN-PM_E.pdf\" xlink:type=\"simple\">http:\/\/www.merck.ca\/assets\/en\/pdf\/products\/PRIMAXIN-PM_E.pdf<\/ext-link> (accessed May 5, 2017)."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpba.2009.02.002","article-title":"The stability of biapenem and structural identification of impurities in aqueous solution","volume":"49","author":"M Xia","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0305-0491(99)00039-5","article-title":"Rat and human membrane dipeptidase: tissue distribution and developmental changes","volume":"123","author":"Y Kera","year":"1999","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.36.7.1577","article-title":"Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I","volume":"36","author":"M Fukasawa","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"D343","DOI":"10.1093\/nar\/gkr987","article-title":"MEROPS: the database of proteolytic enzymes, their substrates and inhibitors","volume":"40","author":"ND Rawlings","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.39.7.1629","article-title":"The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA","volume":"39","author":"S Keynan","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1099\/mic.0.028787-0","article-title":"Identification of genes required for Pseudomonas aeruginosa carnitine catabolism","volume":"155","author":"MJ Wargo","year":"2009","journal-title":"Microbiology"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/bi901935y","article-title":"Structure, mechanism, and substrate profile for Sco3058: the closest bacterial homologue to human renal dipeptidase","volume":"49","author":"JA Cummings","year":"2010","journal-title":"Biochemistry"},{"issue":"Database issue","key":"ref41","doi-asserted-by":"crossref","first-page":"D596","DOI":"10.1093\/nar\/gkq869","article-title":"Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes","volume":"39","author":"GL Winsor","year":"2011","journal-title":"Nucleic Acid Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.88.1.99","article-title":"The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms","volume":"88","author":"H Eagle","year":"1948","journal-title":"J Exp Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157341211797457989","article-title":"Recent advances in stability studies of carbapenems","volume":"7","author":"J Cielecka-Piontek","year":"2011","journal-title":"Current Pharmaceutical Analysis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1185\/03007990903116867","article-title":"Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms","volume":"25","author":"PA Meredith","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T16:01:43Z","timestamp":1720972903000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211096"}},"subtitle":[],"editor":[{"given":"Vijai","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211096","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,2,6]]}}}